\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ shunt\\ placement\\ followed\\ by\\ radiation\\ therapy\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ mass\\ involving\\ the\\ midbrain\\ tectal\\ plate\\ and\\ posterior\\ third\\ ventricle\\.\ \(0\)\
\-\ \\â\\€\\¢\\ secondary\\ obstructive\\ hydrocephalus\\ both\\ lateral\\ ventricles\ \(0\)\
\-\ third\\ ventricle\\ anaplastic\\ astrocytoma\\,\\ grade\\ iii\\,\\ grade\\ 3\ \(0\)\
\-\ \\â\\€\\¢\\ glioma\\ \\(astrocytoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ pineal\\ region\\ tumor\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 56\\ year\\ old\\ man\\ with\\ a\\ two\\ week\\ history\\ of\\ headaches\\ and\\ visual\\ problems\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.14032964342649742\ \(0\)\
\-\ third\\:\\ 0\\.10228199087014918\ \(0\)\
\-\ tectal\\:\\ 0\\.10053846092965167\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.09905522981114316\ \(0\)\
\-\ grade\\:\\ 0\\.09715930725226776\ \(0\)\
\-\ ventricle\\:\\ 0\\.09559374082323666\ \(0\)\
\-\ midbrain\\:\\ 0\\.0803213614847963\ \(0\)\
\-\ anaplastic\\:\\ 0\\.0803213614847963\ \(0\)\
\-\ pineal\\:\\ 0\\.07984750031592196\ \(0\)\
\-\ 56\\:\\ 0\\.06713478075268937\ \(0\)\
\-\ shunt\\:\\ 0\\.06598610849692625\ \(0\)\
\-\ obstructive\\:\\ 0\\.0656220569577597\ \(0\)\
\-\ plate\\:\\ 0\\.0639241631464663\ \(0\)\
\-\ ventricles\\:\\ 0\\.0599959384831307\ \(0\)\
\-\ iii\\:\\ 0\\.05987309521243644\ \(0\)\
\-\ problems\\:\\ 0\\.05904038835231083\ \(0\)\
\-\ visual\\:\\ 0\\.05781904479637603\ \(0\)\
\-\ glioma\\:\\ 0\\.05750259393591926\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.054833654738266235\ \(0\)\
\-\ placement\\:\\ 0\\.05176732676491089\ \(0\)\
\-\ headaches\\:\\ 0\\.04875287073240714\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.04710501803293846\ \(0\)\
\-\ involving\\:\\ 0\\.044752347223929755\ \(0\)\
\-\ week\\:\\ 0\\.043313662960122803\ \(0\)\
\-\ followed\\:\\ 0\\.04275934136386226\ \(0\)\
\-\ radiation\\:\\ 0\\.041854496262124424\ \(0\)\
\-\ enhancing\\:\\ 0\\.039999306460966555\ \(0\)\
\-\ two\\:\\ 0\\.0365273319047165\ \(0\)\
\-\ lymphoma\\:\\ 0\\.03645072588641023\ \(0\)\
\-\ region\\:\\ 0\\.03602389891401959\ \(0\)\
\-\ secondary\\:\\ 0\\.03565716367923593\ \(0\)\
\-\ therapy\\:\\ 0\\.03409911636180019\ \(0\)\
\-\ both\\:\\ 0\\.03257014911471823\ \(0\)\
\-\ metastatic\\:\\ 0\\.03210611050173269\ \(0\)\
\-\ man\\:\\ 0\\.030163161837164165\ \(0\)\
\-\ 3\\:\\ 0\\.029865306368754323\ \(0\)\
\-\ tumor\\:\\ 0\\.029734810471803153\ \(0\)\
\-\ posterior\\:\\ 0\\.029397590279141024\ \(0\)\
\-\ lateral\\:\\ 0\\.02756220963618732\ \(0\)\
\-\ by\\:\\ 0\\.02123687915290858\ \(0\)\
\-\ disease\\:\\ 0\\.020846828973368717\ \(0\)\
\-\ mass\\:\\ 0\\.017738223984292006\ \(0\)\
\-\ history\\:\\ 0\\.017615142353837064\ \(0\)\
\-\ year\\:\\ 0\\.014270227899595742\ \(0\)\
\-\ old\\:\\ 0\\.013058725326302307\ \(0\)\
\-\ \\(\\:\\ 0\\.010781518302147172\ \(0\)\
\-\ \\)\\:\\ 0\\.010649816300198582\ \(0\)\
\-\ \\,\\:\\ 0\\.008080897478127982\ \(0\)\
\-\ a\\:\\ 0\\.005919400027143302\ \(0\)\
\-\ and\\:\\ 0\\.005373403156185626\ \(0\)\
\-\ the\\:\\ 0\\.002063422159755609\ \(0\)\
\-\ with\\:\\ 0\\.0017463309864162648\ \(0\)\
\-\ of\\:\\ 0\\.0017388626984774392\ \(0\)\
\-\ \\.\\:\\ 0\\.0015895314670453554\ \(0\)\
